Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 May 1991Website:
http://www.ionispharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:21:32 GMTDividend
Analysts recommendations
Institutional Ownership
IONS Latest News
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Calif. , June 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd.
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30.
Gain a more comprehensive understanding of Ionis Pharmaceuticals' (IONS) potential performance in the first quarter of 2024 by looking beyond Wall Street's revenue and earnings projections and analyzing estimates for important performance indicators.
Ionis Pharmaceuticals (IONS) has the ideal mix of factors for a potential earnings surpass in its upcoming report. Make sure to be ready with the main predictions.
CARLSBAD, Calif. , April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif.
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
What type of business is Ionis Pharmaceuticals?
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, specializing in research and development of RNA-targeted therapy. It was founded in 1989. The product portfolio includes more than 40 potential drugs aimed at treating a wide range of therapeutic diseases. Currently, the company has three commercially approved drugs in major markets worldwide: SPINRAZA, TEGSEDI, and WAYLIVRA. There are also four drugs undergoing the company's main research: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-L Rx for cardiovascular diseases, and AKCEA-TTR-L Rx for ATTR amyloidosis treatment.
What sector is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals is in the Healthcare sector
What industry is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals is in the Biotechnology industry
What country is Ionis Pharmaceuticals from?
Ionis Pharmaceuticals is headquartered in United States
When did Ionis Pharmaceuticals go public?
Ionis Pharmaceuticals initial public offering (IPO) was on 17 May 1991
What is Ionis Pharmaceuticals website?
https://www.ionispharma.com
Is Ionis Pharmaceuticals in the S&P 500?
No, Ionis Pharmaceuticals is not included in the S&P 500 index
Is Ionis Pharmaceuticals in the NASDAQ 100?
No, Ionis Pharmaceuticals is not included in the NASDAQ 100 index
Is Ionis Pharmaceuticals in the Dow Jones?
No, Ionis Pharmaceuticals is not included in the Dow Jones index
When does Ionis Pharmaceuticals report earnings?
The next expected earnings date for Ionis Pharmaceuticals is 09 August 2024